Conventional or Unconventional Lymph Node Dissection During Resection of Intrahepatic Cholangiocarcinoma

Sponsor
Eastern Hepatobiliary Surgery Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT02526771
Collaborator
(none)
100
1
2
28
3.6

Study Details

Study Description

Brief Summary

The aim of this study is to compare the surgical outcomes of conventional lymph node dissection with unconventional lymph node dissection during resection of Intrahepatic cholangiocarcinoma.

Condition or Disease Intervention/Treatment Phase
  • Procedure: conventional lymph node dissection
  • Procedure: unconventional lymph node dissection
N/A

Detailed Description

Intrahepatic cholangiocarcinoma (ICC) is one of the primary liver cancer, which has higher malignant, more difficult treatment and worse prognosis compared to hepatocellular carcinoma and its incidence continues to rise. The main radical treatment is surgical resection, however, postoperative recurrence rate is extremely high. The 3-year recurrence rate is more than 50%. It is reported that lymph node metastasis rate of ICC is as high as 20% to 65%, which is the most significant factor of the poor prognosis. The probability of lymph node metastasis is 13% when lymph nodes metastasis were not found preoperative or intraoperative. It is highly controversial whether or not to undergo conventional lymph node dissection when lymph nodes metastasis were not found preoperative or intraoperative . A number of researchers approved of lymph node dissection at that situation. However, some authors such as Kim suggest that lymph node resection is not necessary. Others such as Yang think should consider in different condition. Clark CJ thinks that the evidence for dissection or not of lymph node is insufficient in view of the above reasons, the investigators have planned to implement a randomized controlled study to confirm the prognostic value of conventional or unconventional lymph node dissection during resection of Intrahepatic cholangiocarcinoma.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Care Provider, Investigator)
Primary Purpose:
Treatment
Official Title:
A Randomized Controlled Study of Conventional or Unconventional Lymph Node Dissection During Resection of Intrahepatic Cholangiocarcinoma
Study Start Date :
Aug 1, 2015
Anticipated Primary Completion Date :
Dec 1, 2017
Anticipated Study Completion Date :
Dec 1, 2017

Arms and Interventions

Arm Intervention/Treatment
Experimental: conventional lymph node dissection

conventional lymph node dissection during resection of intrahepatic cholangiocarcinoma

Procedure: conventional lymph node dissection
conventional lymph node dissection during resection of intrahepatic cholangiocarcinoma

Active Comparator: unconventional lymph node dissection

unconventional lymph node dissection during resection of intrahepatic cholangiocarcinoma

Procedure: unconventional lymph node dissection
unconventional lymph node dissection during resection of intrahepatic cholangiocarcinoma

Outcome Measures

Primary Outcome Measures

  1. overall survival [five years]

Secondary Outcome Measures

  1. disease-free survival [five years]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Male or female patients > 18 years and <=70 years of age.

  • Diagnosis of intrahepatic cholangiocarcinoma ( through imaging, serology, intraoperative frozen, etc.)

  • No lymph node metastasis preoperatively or intraoperatively.

  • Tumors can be completely resected.

  • Criteria of liver function: Child A-B level, serum bilirubin ≤ 1.5 times the upper limit of normal value, alanine aminotransferase and aspartate aminotransferase ≤ 2 times the upper limit of normal value.

  • Patients who can understand this trial and have signed information consent. Exclusion Criteria:Lymph node metastasis preoperatively.

  • Tumors can not be resected .

  • Patients with apparent cardiac, pulmonary, cerebral and renal dysfunction, which may affect the treatment of Intrahepatic cholangiocarcinoma.

  • Patients with a medical history of other malignant tumors.

  • Subjects participating in other clinical trials.

  • liver function:Child C.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Eastern hepatobilliary surgery hospital Shanghai Shanghai China 200438

Sponsors and Collaborators

  • Eastern Hepatobiliary Surgery Hospital

Investigators

  • Study Chair: Shen Feng, MD, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
ShenFeng, vice president of the Eastern Hepatobiliary Surgery Hospital, Eastern Hepatobiliary Surgery Hospital
ClinicalTrials.gov Identifier:
NCT02526771
Other Study ID Numbers:
  • EHBHLND-2015-8-10
First Posted:
Aug 18, 2015
Last Update Posted:
Apr 1, 2016
Last Verified:
Mar 1, 2016
Keywords provided by ShenFeng, vice president of the Eastern Hepatobiliary Surgery Hospital, Eastern Hepatobiliary Surgery Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 1, 2016